Tumor-targeting intracellular drug delivery based on dual acid/reduction-degradable nanoassemblies with ketal interface and disulfide core locations

2019 ◽  
Vol 10 (22) ◽  
pp. 2840-2853 ◽  
Author(s):  
Arman Moini Jazani ◽  
Newsha Arezi ◽  
Chaitra Shetty ◽  
Sung Hwa Hong ◽  
Haowen Li ◽  
...  

Dual acid/reduction-degradable block copolymer nanoassemblies both at core/corona interfaces and in micellar cores leading to synergistic and accelerated drug release for robust tumor-targeting intracellular drug delivery.

2015 ◽  
Vol 3 (38) ◽  
pp. 7594-7603 ◽  
Author(s):  
Zhuxian Zhou ◽  
Jianbin Tang ◽  
Qihang Sun ◽  
William J. Murdoch ◽  
Youqing Shen

Tumor-targeting camptothecin (CPT)-conjugated nanoparticles with high stability and GSH-triggered drug release were developed for cancer targeting drug delivery.


2019 ◽  
Vol 10 (13) ◽  
pp. 1554-1568 ◽  
Author(s):  
Jung Kwon Oh

Review on recent strategies to synthesize novel disulfide-containing reductively-degradable block copolymers and their nanoassemblies as being classified with the number, position, and location of the disulfide linkages toward effective tumor-targeting intracellular drug delivery exhibiting enhanced release of encapsulated drugs.


2021 ◽  
Vol 16 (7) ◽  
pp. 1029-1036
Author(s):  
Hongzhu Wang ◽  
Mengxun Chen ◽  
Liping Song ◽  
Youju Huang

A key challenge for nanoparticles-based drug delivery system is to achieve manageable drug release in tumour cell. In this study, a versatile system combining photothermal therapy and controllable drug release for tumour cells using temperature-sensitive block copolymer coupled Au NRs@SiO2 is reported. While the Au NRs serve as hyperthermal agent and the mesoporous silica was used to improve the drug loading and decrease biotoxicity. The block copolymer acted as “gatekeeper” to regulate the release of model drug (Doxorubicin hydrochloride, DOX). Through in vivo and in vitro experiments, we achieved the truly controllable drug release and photothermal therapy with the collaborative effect of the three constituents of the nanocomposites. The reported nanocomposites pave the way to high-performance controllable drug release and photothermal therapy system.


2009 ◽  
Vol 20 (6) ◽  
pp. 1095-1099 ◽  
Author(s):  
Ling-Yan Tang ◽  
Yu-Cai Wang ◽  
Yang Li ◽  
Jin-Zhi Du ◽  
Jun Wang

2007 ◽  
Vol 8 (6) ◽  
pp. 1966-1972 ◽  
Author(s):  
Simona Cerritelli ◽  
Diana Velluto ◽  
Jeffrey A. Hubbell

2018 ◽  
Vol 30 (3) ◽  
pp. 1870020 ◽  
Author(s):  
Xing Guo ◽  
Lin Wang ◽  
Kayla Duval ◽  
Jing Fan ◽  
Shaobing Zhou ◽  
...  

2007 ◽  
Vol 7 (12) ◽  
pp. 4612-4617 ◽  
Author(s):  
Franck Lacoeuille ◽  
Emmanuel Garcion ◽  
Jean-Pierre Benoit ◽  
Alf Lamprecht

As non-phagocytic eukaryotic cells can internalize particles <1 μm in size, small size (25 to 110 nm) lipid nanocapsules (LNC) are proposed for the intracellular drug delivery of anticancer drugs to cancer cells. LNC ofdifferent diameters were loaded with etoposide or paclitaxel and subsequently tested for drug release kinetics and their efficiency to reduce cancer cell growth in cell culture. Relative high drug loads could be achieved and sustained drug release can be provided over a period ofseveral days (etoposide) up to a few weeks (paclitaxel). While particle size exhibited only minor influences on the release kinetics, higher initial drug load led to a distinctly lower burst release. In a cancer cell culture model, etoposide or paclitaxel LNC showed a 4-fold or 40-fold higher efficiency, respectively than the drug solution while blank LNC were found to be less toxic than the pure drug at equivalent concentrations. The uptake and intracellular accumulation ofLNC was confirmed by confocal laser scanning microscopy after fluorescence labeling of the nanocarriers. This nanoparticulate system is able to achieve efficient intracellular drug concentrations and seems to be therefore a promising therapeutic approach in cancer treatment.


Sign in / Sign up

Export Citation Format

Share Document